Gluconacetobacter xylinum genome traceless editing method

By constructing suicide plasmids and induction plasmids, using I-SceI enzyme cleavage sites for traceless editing, the problem of 'scar' left in genome editing of acetobacter xyloconate was solved, and traceless knockout, back-compensation and replacement were achieved and insertion operations have enhanced its application value in the food industry.

CN118910114APending Publication Date: 2024-11-08SHANGHAI JIAOTONG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411157073.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing technology cannot achieve traceless editing of the genome of Acetobacter xyloconate, especially the traceless gene editing has not been successful, resulting in the genome editing leaving a 'scar', affecting its application in the food industry.

Method used

By constructing suicide plasmids and induction plasmids containing Donor fragments, the cells' own homologous recombination system is used to perform traceless knockout, recompense, replacement and insertion operations guided by I-SceI enzyme cleavage site, and achieve xyloconate vinegar Traceless editing of the bacillus genome.

Benefits of technology

The traceless editing of the genome of Acetobacter xyloconate was achieved, and screening marks were avoided on the genome, and used to build BC stable, high-yield or excellent performance strains, enhancing its application value in the food industry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910114A_ABST
    Figure CN118910114A_ABST
Patent Text Reader

Abstract

The invention relates to a method for traceless editing of a gluconacetobacter xylinum genome, which comprises the following steps: respectively constructing a suicide plasmid containing a Donor fragment and an induction plasmid containing homing endonuclease (I-SceI), electrically transferring the suicide plasmid and the induction plasmid into competent cells of gluconacetobacter xylinum in sequence, and carrying out homologous recombination twice to obtain a mutant strain for traceless editing of the gluconacetobacter xylinum genome. The method disclosed by the invention realizes traceless knockout, refilling, replacement and insertion operations on the gluconacetobacter xylinum genome, can be used for construction work of strains with stable high yield of BC or excellent performance, and is convenient to apply to industries such as food and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a technology in the field of bioengineering, in particular to a method for seamlessly editing the genome of Gluconacetobacter xylinum. Background Art

[0002] Bacterial nanocellulose (BC) is a natural nanopolymer produced by microbial fermentation, which has great application value in the food, medicine and materials industries. As the most studied bacterium with the strongest BC synthesis ability, the genetic modification technology of Komagataeibacterxylinus is still weak, especially scarless gene editing has not been successful. The genetic modification technologies currently applied to Komagataeibacterxylinus include gene expression regulation technologies such as sRNA and CRISPRi, and genome editing technologies such as homologous recombination and site-specific recombination. However, gene expression regulation technology cannot achieve genome editing, and the homologous recombination and site-specific recombination technologies reported above will leave "scars" on the genome. It is very important and urgent to develop a genome-scarless editing method for this bacterium to improve the metabolic synthesis ability of germplasm and facilitate the application of its products in the food and other industries. Summary of the invention

[0003] In view of the above-mentioned deficiencies in the prior art, the present invention proposes a method for scarless editing of the genome of Gluconacetobacter xylonitrile, which realizes scarless knockout, backfilling, replacement and insertion operations on the genome of Gluconacetobacter xylonitrile, and can be used for the construction of BC stable high-yield or excellent performance strains, and is convenient for application in the food industry and the like.

[0004] The present invention is achieved through the following technical solutions:

[0005] The present invention relates to a method for seamlessly editing the genome of Gluconacetobacter xylinum, comprising:

[0006] 1) Construct a suicide plasmid containing the Donor fragment and an inducible plasmid containing a homing endonuclease (I-SceI);

[0007] 2) The suicide plasmid is electroporated into competent cells of Gluconacetobacter xylinum, and the Donor fragment is integrated into the genome using the cell's own homologous recombination system to obtain the first recombinant mutant strain;

[0008] 3) The inducing plasmid is electroporated into the competent cells of the first recombinant mutant strain, and IPTG induces the expression of I-SceI, so that it acts on the I-SceI restriction site integrated in the genome, loses the resistance gene, and obtains the second recombinant mutant strain;

[0009] 4) The second recombinant mutant was subcultured in a non-resistant HS medium to lose the inducing plasmid, thereby obtaining a mutant strain with no scar editing of the genome of Glucose Acetobacter xylinum.

[0010] The scarless editing includes scarless knockout, scarless filling, scarless replacement and scarless insertion.

[0011] The scarless knockout means that in step 1), the Donor fragment is a fragment composed of the Ori replicon, the upstream homologous arm of the knockout gene, the homologous fragment consistent with the 35bp sequence downstream of the knockout gene, the I-SceI restriction site, the resistance gene, the I-SceI restriction site and the downstream homologous arm of the knockout gene.

[0012] The seamless complementation means that in step 1), the Donor fragment is a fragment composed of the Ori replicon, the upstream homologous arm of the complementing gene, the complementing gene, the homologous fragment consistent with the 35bp sequence downstream of the complementing gene, the I-SceI restriction site, the resistance gene, the I-SceI restriction site and the downstream homologous arm of the complementing gene.

[0013] The scarless replacement means that in step 1), the Donor fragment is a fragment composed of the Ori replicon, the upstream homologous arm of the replacement gene, the gene to be replaced, the homologous fragment consistent with the 35bp sequence downstream of the replacement gene, the I-SceI restriction site, the resistance gene, the I-SceI restriction site and the downstream homologous arm of the replacement gene.

[0014] The scarless insertion means that in step 1), the Donor fragment is a fragment consisting of the Ori replicon, the homologous arm upstream of the insertion site, the I-SceI restriction site, the resistance gene, the I-SceI restriction site, the homologous fragment consistent with the 35bp sequence upstream of the insertion site, the gene or element and the homologous arm downstream of the insertion site.

[0015] The I-SceI enzyme is expressed by inducing IPTG, and the concentration of IPTG used is 0.1-1 mM.

[0016] The sequence of the I-SceI restriction site is shown in Seq ID No.1.

[0017] The resistance gene is an ampicillin resistance gene or a spectinomycin resistance gene.

[0018] The inducible plasmid is inserted into the pSEVA331Bb plasmid by inserting the P in the pTKRed plasmid and the pCas9 plasmid. trc -lacI q The inducible plasmid includes pBBR1 Rep protein, OriV replicon, P trc -lacIq Inducible promoter, I-SceI gene, lambdat0 terminator and chloramphenicol resistance gene.

[0019] The subculture refers to: culturing the second recombinant mutant containing the induced plasmid in a non-resistant HS medium, taking single colonies and spotting them on HS plates containing chloramphenicol resistance and non-resistance respectively; selecting colonies that grow on non-resistance HS plates and do not grow on chloramphenicol resistance HS plates, and verifying the loss of the induced plasmid by PCR; if there is no band in the PCR identification gel image, the loss is successful, otherwise the bacterial solution is subcultured until the genome-scarless editing mutant of Gluconobacter xylinus is obtained, which specifically includes:

[0020] 1) The second recombinant mutant containing the inducing plasmid was inoculated into 30 mL of HS liquid medium containing 5 U / L cellulase without resistance, and cultured at 30° C. and 180 rpm;

[0021] 2) Wait for the bacterial solution OD 600 At 0.4-0.8, take 20-100 μL of bacterial solution and streak it on a non-resistant HS plate and culture it at 30℃ for 1-3 days;

[0022] 3) Spot single colonies onto HS plates containing 340 μg / mL chloramphenicol-resistant and non-resistant bacteria, and culture at 30°C for 1-2 days;

[0023] 4) Select the colonies that grow on the non-resistant HS plate but not on the chloramphenicol-resistant HS plate, and verify the loss of the induced plasmid by PCR. If there is no band in the PCR identification gel image, the loss is successful;

[0024] 5) If the loss fails, take 1 mL of the bacterial solution in step 1) for subculture and spot it on HS plates with different resistances, and repeat the above steps until a strain that successfully loses the induced plasmid is obtained, that is, a mutant strain of the genome of Glucose Acetobacter xylinum with no scar editing.

[0025] The present invention relates to an application of a genome-scarless editing mutant strain of gluconic acetobacter xylonitrile obtained based on the method. The genome-scarless editing mutant strain of gluconic acetobacter xylonitrile is cultured on a plate, and then a BC film is obtained through primary seed culture, secondary seed culture and tertiary fermentation culture, and the BC yield is determined after post-fermentation treatment.

[0026] The applications specifically include:

[0027] 1) Plate culture: The mutant strain of Glucose Acetobacter xylinum that has successfully achieved seamless genome editing is streaked on a non-resistant HS plate and cultured at 30°C for 1-3 days;

[0028] 2) Primary seed culture: scrape a ring of colonies from the plate, dilute with 1 mL of sterile water, and calculate the initial OD600 Inoculate 0.02-0.05 of the inoculum into a 250 mL first-level seed bottle containing 30 mL of HS liquid medium and culture at 30°C for 24 h-26 h;

[0029] 3) Secondary seed culture: Take 2.4 mL of the primary seed solution and transfer it to a 250 mL secondary seed bottle containing 30 mL of HS liquid medium at an inoculum volume of 8%, and culture at 30°C for 24-26 hours;

[0030] 4) Tertiary fermentation culture: Take 3 mL of the secondary seed solution and transfer it to a 250 mL tertiary fermentation bottle containing 50 mL of fermentation medium at a 6% inoculum amount, and culture it at 30°C for 7-8 days;

[0031] 5) Post-fermentation treatment: remove the BC membrane and rinse off the culture medium and other impurities with tap water; add 0.1 mol / L NaOH solution and boil at 80℃ for 0.5-1h to remove the bacteria; soak in tap water for several times until the BC is milky white and the pH is 7.0; dry in a constant temperature drying oven at 80℃, weigh and calculate the BC yield after constant weight. Technical Effects

[0032] The present invention constructs a suicide plasmid and an inducible plasmid, and realizes traceless knockout, backfilling, replacement and insertion operations on the target gene on the xylindoleacetobacter genome through two homologous recombination operations. Compared with the prior art, the present invention does not leave any screening markers (such as resistance genes) after editing the genes on the xylindoleacetobacter genome, and can be used for the construction of BC stable high-yield or excellent performance strains. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Schematic diagram of the method for scarless knockout of the genome of Gluconacetobacter xylinum;

[0034] Figure 2 Schematic diagram of the method for seamlessly filling the genome of Gluconacetobacter xylinum;

[0035] Figure 3 Schematic diagram of the method for scarless replacement of the genome of Gluconacetobacter xylinum;

[0036] Figure 4 Schematic diagram of the method for scarless insertion into the genome of Gluconacetobacter xylinum;

[0037] Figure 5 is the map of the inducing plasmid;

[0038] Figure 6 The DNA sequencing results and BC production diagram of the acsD gene scarless knockout mutant strain;

[0039] Figure 7The DNA sequencing results and BC production diagram of the acsD gene scarless complement mutant strain;

[0040] Figure 8 The DNA sequencing results and BC production diagram of the bcsD gene scarless substitution mutant strain;

[0041] Fig. 9 P J23104 DNA sequencing results and BC production graph of the +RBS scarless insertion mutant. DETAILED DESCRIPTION Example 1

[0042] This embodiment relates to the construction and fermentation of a seamless knockout mutant of the acsD gene, which specifically includes:

[0043] 1) Construction of suicide plasmid: Using K. xylinus ATCC 53524 genome as template, H1-F and H1-R, H2-F and H2-R as primers, PCR amplification obtained the upper and lower homologous arm fragments of acsD gene, the sizes of which were 551 bp and 532 bp respectively; using pUC19 plasmid as template, H3-F and H3-R, H4-F and H4-R as primers, PCR amplification obtained the replicon fragment and ampicillin resistance gene fragment, the sizes of which were 827 bp and 1192 bp respectively; The PCR one-step directional cloning kit was used to connect the four fragments. Using Q1-F and Q1-R as primers, PCR was used to verify the plasmid construction. The size of the correctly connected plasmid was 2577bp. Using Q1-F, Q1-R, Q2-F and Q2-R as primers, it was sent to Qingke Biotechnology Co., Ltd. for sequencing, and a suicide plasmid consisting of the Ori replicon and the Donor fragment (the upstream homologous arm of the acsD gene, the homologous fragment consistent with the 35bp sequence downstream of the acsD gene, the I-SceI restriction site, the ampicillin resistance gene, the I-SceI restriction site and the downstream homologous arm of the acsD gene) was successfully obtained.

[0044] 2) Electroporation and verification of suicide plasmid: The suicide plasmid was electroporated into the competent cells of K.xylinusATCC 53524, and after recovery, it was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and cultured at 30°C for 3 days; a plurality of transformants were randomly selected to 50 μL HS medium containing 100 μg / mL ampicillin resistance and 5U / L cellulase, and cultured at 30°C for 2 days; Q3-F and Q3-R were used as primers, and PCR was used to verify the recombination of the Donor fragment, and the K.xylinusATCC53524 strain (1797bp) was used as a control. The correct transformant had a band at 2533bp; 50 μL of bacterial solution was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and cultured at 30°C for 2 days, i.e., the first recombinant mutant strain.

[0045] 3) Inducing plasmid (map as shown Figure 5 The construction of the plasmid was as shown in Figure 2: pSEVA331Bb plasmid (#78269, https: / / www.addgene.org / ) was used as a template, H5-F and H5-R were used as primers, and PCR amplification was performed to obtain a 2870 bp plasmid vector fragment; pTKRed plasmid (#41062, https: / / www.addgene.org / ) was used as a template, H6-F and H6-R were used as primers, and PCR amplification was performed to obtain a 722 bp I-SceI gene fragment; pCas9 (#62225, https: / / www.addgene.org / ) plasmid was used as a template, H7-F and H7-R were used as primers, and PCR amplification was performed to obtain a 1479 bp P trc -lacI q Promoter fragment; The PCR one-step directional cloning kit was used to connect the three fragments. Using Q4-F and Q4-R as primers, PCR was used to verify the plasmid construction. The size of the correctly connected plasmid was 3775bp. Using Q5-F, Q5-R, Q6-F and Q6-R as primers, it was sent to Qingke Biotechnology Co., Ltd. for sequencing, and the induced plasmid was successfully obtained.

[0046] 4) Electroporation and verification of the inducing plasmid: The inducing plasmid was electroporated into the competent cells of the first recombinant mutant strain, and after recovery, it was spread on a HS plate containing 100 μg / mL ampicillin resistance and 340 μg / mL chloramphenicol resistance, and cultured at 30°C for 3 days; a plurality of transformants were randomly selected to 50 μL HS medium containing 100 μg / mL ampicillin resistance, 340 μg / mL chloramphenicol resistance and 5U / L cellulase, and cultured at 30°C for 2 days; Q4-F and Q4-R were used as primers, and PCR was used to verify the electroporation of the inducing plasmid, and the first recombinant mutant strain (0 bp) was used as a control. The correct transformant had a band at 3775 bp; 50 μL of bacterial solution was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and 340 μg / mL chloramphenicol resistance, and cultured at 30°C for 2 days, i.e., the first recombinant mutant strain containing the inducing plasmid was obtained.

[0047] 5) IPTG-induced loss of resistance gene: The first recombinant mutant containing the inducible plasmid was inoculated into 4 mL HS liquid medium containing 340 μg / mL chloramphenicol resistance and 5 U / L cellulase and different concentrations of IPTG (0.1 / 0.3 / 0.5 / 0.7 / 0.9 / 1 mM), and cultured at 30°C and 180 rpm. 600 At about 0.5, 20 μL of bacterial solution was streaked on a HS plate containing 340 μg / mL chloramphenicol resistance and corresponding concentration of IPTG, and cultured at 30°C for 3 days; single colonies were spotted on HS plates containing 100 μg / mL ampicillin resistance and no resistance, respectively, and cultured at 30°C for 2 days; colonies that grew on HS plates without resistance and did not grow on HS plates with ampicillin resistance were selected, and Q3-F and Q3-R were used as primers to verify the loss of ampicillin resistance genes on the genome by PCR, and the strain not induced by IPTG (2533 bp) was used as a control. The correct transformant had a band at 1326 bp; 50 μL of bacterial solution was applied to a HS solid plate containing 340 μg / mL chloramphenicol resistance and cultured at 30°C for 2 days, which was the second recombinant mutant containing the induced plasmid.

[0048] 6) Loss of inducing plasmid in subculture: The second recombinant mutant containing the inducing plasmid was inoculated into 30 mL HS liquid medium without resistance containing 5 U / L cellulase, and cultured at 30°C and 180 rpm. 600When the p value was about 0.6, 50 μL of bacterial solution was streaked on a non-resistant HS plate and cultured at 30°C for 2 days; single colonies were spotted on HS plates containing 340 μg / mL chloramphenicol resistance and non-resistant, respectively, and cultured at 30°C for 2 days; colonies that grew on non-resistant HS plates but did not grow on chloramphenicol-resistant HS plates were selected, and Q4-F and Q4-R were used as primers to verify the loss of the induced plasmid by PCR, and the ΔacsD second recombinant mutant strain (3775bp) containing the induced plasmid was used as a control, and the correct transformant had no bands; 50 μL of bacterial solution was applied to a HS solid plate and cultured at 30°C for 2 days, which was the acsD gene scarless knockout mutant.

[0049] 7) Verification and fermentation of acsD gene seamless knockout mutants: Using Q3-F and Q3-R as primers, PCR was used to verify the gene knockout, and K. xylinus ATCC 53524 (1797 bp) was used as a control. The correct transformant had a band at 1326 bp; using Q3-F and Q3-R as primers, the DNA was sent to Qingke Biotechnology Co., Ltd. for sequencing. The DNA sequencing results are as follows: Figure 6 As shown in A, it indicates that the acsD gene was successfully knocked out without a trace. K. xylinus ATCC 53524 strain and the acsD gene without a trace knockout mutant were streaked on a non-resistant HS plate and cultured at 30°C for 2 days; a loop of colonies was scraped off the plate, diluted with 1 mL of sterile water, and the initial OD was calculated. 600 Inoculate 0.04% of the inoculum into a 250mL first-level seed bottle containing 30mL HS liquid culture medium, and incubate at 30℃ for 24h; take 2.4mL of the first-level seed liquid, transfer it to a 250mL second-level seed bottle containing 30mL HS liquid culture medium at an inoculum of 8%, and incubate at 30℃ for 24h; take 3mL of the second-level seed liquid, transfer it to a 250mL third-level fermentation bottle containing 50mL fermentation medium at an inoculum of 6%, and incubate at 30℃ for 8 days; take out the BC membrane, and rinse off the culture medium and other impurities with tap water; add 0.1mol / L NaOH solution, and boil at 80℃ for 1h to remove the bacteria; soak in tap water several times until the BC is milky white and the pH is 7.0; dry it in a constant temperature drying oven at 80℃, weigh it after constant weight, and calculate the BC yield. Figure 6 As shown in B, compared with K. xylinus ATCC 53524, the BC production of the acsD gene seamless knockout mutant was reduced by 98.9%, but the cells did not completely lose the ability to synthesize BC. This result shows that the acsD gene is not an essential gene for BC synthesis, but plays a very important role in regulating BC synthesis. The sequencing results of the strain and the BC fermentation yield both show that Figure 1The K. xylinus genome scarless knockout method shown was successfully developed, which can be used to knock out target genes to study their specific functions in organisms, or to knock out bypass or inhibitory genes for breeding of BC high-yield strains.

[0050] HS medium consisted of 20 g / L glucose, 5 g / L peptone, 5 g / L yeast powder, 6.8 g / L Na2HPO4·12H2O and 1.15 g / L citric acid monohydrate, pH = 6.0.

[0051] The fermentation medium consisted of 3303.5 mg / L ammonium sulfate, 993.5 mg / L potassium dihydrogen phosphate, 246.5 mg / L magnesium sulfate heptahydrate, 40 g / L sucrose, and 10 g / L corn steep liquor, with a pH of 5.0.

[0052] The required primers are shown in the following table: Example 2

[0053] This embodiment relates to the construction and fermentation of an acsD gene seamless complementation mutant strain, which specifically includes:

[0054] 1) Construction of suicide plasmid: Using K.xylinus ATCC 53524 genome as template, H8-F and H8-R, H2-F and H9-R as primers, PCR amplification obtained the upper and lower homologous arm fragments of acsD gene, the sizes of which were 1133 bp and 1301 bp respectively; using pUC19 plasmid as template, H3-F and H3-R, H9-F and H4-R as primers, PCR amplification obtained the replicon fragment and ampicillin resistance gene fragment, the sizes of which were 827 bp and 1192 bp respectively; using K.xylinus ATCC 53524 genome as template, H10-F and H10-R as primers, PCR amplification obtained the acsD gene fragment, the size of which was 516 bp; The PCR one-step directional cloning kit was used to connect the five fragments. Using Q1-F and Q1-R as primers, PCR was used to verify the plasmid construction. The size of the correctly connected plasmid was 4379 bp. Using Q1-F, Q1-R, Q2-F, Q2-R, Q7-F and Q7-R as primers, the plasmid was sent to Qingke Biotechnology Co., Ltd. for sequencing, and a suicide plasmid consisting of the Ori replicon and the Donor fragment (the upstream homologous arm of the acsD gene, the acsD gene, the homologous fragment consistent with the 35 bp sequence downstream of the acsD gene, the I-SceI restriction site, the ampicillin resistance gene, the I-SceI restriction site and the downstream homologous arm of the acsD gene) was successfully obtained.

[0055] 2) Electroporation and verification of suicide plasmid: The suicide plasmid was electroporated into the competent cells of the acsD gene scarless knockout mutant obtained in Example 1, and after recovery, it was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and cultured at 30°C for 3 days; a plurality of transformants were randomly selected to 50 μL HS medium containing 100 μg / mL ampicillin resistance and 5U / L cellulase, and cultured at 30°C for 2 days; Q8-F and Q8-R were used as primers, and PCR was used to verify the recombination of the Donor fragment, and the acsD gene scarless knockout mutant (2578bp) was used as a control. The correct transformant had a band at 4256bp; 50 μL of bacterial solution was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and cultured at 30°C for 2 days, i.e., the first recombinant mutant.

[0056] 3) Electroporation and verification of the inducing plasmid: The inducing plasmid obtained in Example 1 was electroporated into the competent cells of the first recombinant mutant strain, and after recovery, it was applied to a HS plate containing 100 μg / mL of ampicillin resistance and 340 μg / mL of chloramphenicol resistance, and cultured at 30°C for 3 days; a plurality of transformants were randomly selected to 50 μL HS medium containing 100 μg / mL of ampicillin resistance, 340 μg / mL of chloramphenicol resistance and 5U / L cellulase, and cultured at 30°C for 2 days; using Q4-F and Q4-R as primers, PCR was used to verify the electroporation of the inducing plasmid, and the first recombinant mutant strain (0 bp) was used as a control. The correct transformant had a band at 3775 bp; 50 μL of bacterial solution was applied to a HS solid plate containing 100 μg / mL of ampicillin resistance and 340 μg / mL of chloramphenicol resistance, and cultured at 30°C for 2 days, i.e., the first recombinant mutant strain containing the inducing plasmid was obtained.

[0057] 4) IPTG-induced loss of resistance gene: The first recombinant mutant containing the inducible plasmid was inoculated into 4 mL HS liquid medium containing 340 μg / mL chloramphenicol resistance and 5 U / L cellulase and 0.7 mM IPTG, and cultured at 30°C and 180 rpm. 600When the p value was about 0.4, 50 μL of bacterial solution was streaked on a HS plate containing 340 μg / mL chloramphenicol resistance and 0.7 mM IPTG, and cultured at 30°C for 2 days; single colonies were spotted on HS plates containing 100 μg / mL ampicillin resistance and no resistance, respectively, and cultured at 30°C for 1 day; colonies that grew on HS plates without resistance and did not grow on HS plates with ampicillin resistance were selected, and Q8-F and Q8-R were used as primers to verify the loss of the ampicillin resistance gene on the genome by PCR, and the strain not induced by IPTG (4256 bp) was used as the control. The correct transformant had a band at 3049 bp; 50 μL of bacterial solution was applied to a HS solid plate containing 340 μg / mL chloramphenicol resistance and cultured at 30°C for 2 days, which was the second recombinant mutant containing the induced plasmid.

[0058] 5) Loss of inducing plasmid in subculture: The second recombinant mutant containing the inducing plasmid was inoculated into 30 mL HS liquid medium containing 5 U / L cellulase without resistance, and cultured at 30°C and 180 rpm. 600 When the p value was about 0.4, 60 μL of bacterial solution was streaked on a non-resistant HS plate and cultured at 30°C for 3 days; single colonies were spotted on HS plates containing 340 μg / mL chloramphenicol resistance and non-resistant, respectively, and cultured at 30°C for 2 days; transformants grew on both resistant HS plates, 1 mL of bacterial solution was taken for subculture and spotted on HS plates with different resistances; colonies that grew on non-resistant HS plates but not on chloramphenicol-resistant HS plates were selected, and Q4-F and Q4-R were used as primers to verify the loss of the induced plasmid by PCR, and the second recombinant mutant strain (3775 bp) containing the induced plasmid was used as a control, and the correct transformant had no bands; 50 μL of bacterial solution was applied to a HS solid plate and cultured at 30°C for 2 days, i.e., the acsD gene seamless complement mutant strain was obtained.

[0059] 6) Verification and fermentation of acsD gene scarless complement mutant strain: Using Q8-F and Q8-R as primers, PCR was performed to verify the gene complementation, and the acsD gene scarless knockout mutant strain (2578bp) was used as a control. The correct transformant had a band at 3049bp; using Q8-F, Q8-R, Q9-F and Q9-R as primers, the DNA was sent to Qingke Biotechnology Co., Ltd. for sequencing. The DNA sequencing results are as follows: Figure 7 As shown in A, the acsD gene was successfully complemented in the acsD gene seamless knockout mutant. The acsD gene seamless knockout mutant and the acsD gene seamless complemented mutant were selected, and fermentation and post-treatment were performed according to step 7) in Example 1. The measured BC yield was as follows: Figure 7As shown in B, compared with the acsD gene scarless knockout mutant, the BC production of the acsD gene scarless complement mutant was significantly improved (increased by 97.4%), and compared with the K. xylinus ATCC 53524 strain, the BC production was restored (no significant difference), which further proved that acsD is an important gene for BC synthesis; the sequencing results of the strain and the BC fermentation yield both showed Figure 2 The K. xylinus genome scarless complementation method shown in the figure has been successfully developed. This method can accurately complement the target gene in the genome in situ, and therefore has unique application value for studying the role of target genes with unknown functions in organisms (for example, the regulation of biosynthesis and metabolism).

[0060] The required primers are shown in the following table: Example 3

[0061] This embodiment relates to the construction and fermentation of a bcsD gene seamless replacement mutant strain, which specifically includes:

[0062] 1) Construction of suicide plasmid: Using K. xylinus ATCC 53524 genome as template, H11-F and H11-R, H2-F and H12-R as primers, PCR amplification obtained the upper and lower homologous arm fragments of acsD gene, with sizes of 1133 bp and 1301 bp respectively; using pUC19 plasmid as template, H3-F and H3-R, H12-F and H4-R as primers, PCR amplification obtained the replicon fragment and ampicillin resistance gene fragment, with sizes of 827 bp and 1192 bp respectively; using gene-synthesized pET28a-bcsD plasmid as template, H13-F and H13-R as primers, PCR amplification obtained the bcsD gene fragment (Seq ID No. 46), with a size of 510 bp; The PCR one-step directional cloning kit was used to connect the five fragments. Using Q1-F and Q1-R as primers, PCR was used to verify the plasmid construction. The size of the correctly connected plasmid was 4373 bp. Using Q1-F, Q1-R, Q2-F, Q2-R, Q7-F and Q7-R as primers, the plasmid was sent to Qingke Biotechnology Co., Ltd. for sequencing, and a suicide plasmid consisting of the Ori replicon and the Donor fragment (the upstream homologous arm of the acsD gene, the bcsD gene, a homologous fragment consistent with the 35 bp sequence downstream of the acsD gene, the I-SceI restriction site, the ampicillin resistance gene, the I-SceI restriction site and the downstream homologous arm of the acsD gene) was successfully obtained.

[0063] 2) Electroporation and verification of suicide plasmid: The suicide plasmid was electroporated into the competent cells of K.xylinusATCC 53524, and after recovery, it was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and cultured at 30°C for 3 days; a plurality of transformants were randomly selected to 50 μL HS medium containing 100 μg / mL ampicillin resistance and 5U / L cellulase, and cultured at 30°C for 2 days; Q8-F and Q8-R were used as primers, and PCR was used to verify the recombination of the Donor fragment, and K.xylinusATCC53524 (3049 bp) was used as a control. The correct transformant had a band at 4250 bp; 50 μL of bacterial solution was spread on a HS solid plate containing 100 μg / mL ampicillin resistance and cultured at 30°C for 2 days, i.e., the first recombinant mutant strain.

[0064] 3) Electroporation and verification of the inducing plasmid: The inducing plasmid obtained in Example 1 was electroporated into the competent cells of the first recombinant mutant strain, and after recovery, it was spread on a HS plate containing 100 μg / mL ampicillin resistance and 340 μg / mL chloramphenicol resistance, and cultured at 30°C for 3 days; a plurality of transformants were randomly selected and plated on a HS plate containing 100 μg / mL ampicillin resistance, 340 μg / mL chloramphenicol resistance, and cultured at 30°C for 3 days; μg / mL chloramphenicol resistance and 5U / L cellulase in 50μL HS medium, and culture at 30℃ for 2 days; using Q4-F and Q4-R as primers, PCR was used to verify the transfer of the induced plasmid, and the first recombinant mutant strain (0bp) was used as a control. The correct transformant had a band at 3775bp; 50μL of bacterial liquid was spread on a HS solid plate containing 100μg / mL ampicillin resistance and 340μg / mL chloramphenicol resistance, and cultured at 30℃ for 2 days, which was the first recombinant mutant strain containing the induced plasmid.

[0065] 4) IPTG-induced loss of resistance gene: The first recombinant mutant containing the inducible plasmid was inoculated into 4 mL HS liquid medium containing 340 μg / mL chloramphenicol resistance and 5 U / L cellulase and 0.7 mM IPTG, and cultured at 30°C and 180 rpm. 600When the p value was about 0.4, 60 μL of bacterial solution was streaked on a HS plate containing 340 μg / mL chloramphenicol resistance and 0.7 mM IPTG, and cultured at 30°C for 3 days; single colonies were spotted on HS plates containing 100 μg / mL ampicillin resistance and no resistance, respectively, and cultured at 30°C for 2 days; colonies that grew on HS plates without resistance and did not grow on HS plates with ampicillin resistance were selected, and Q8-F and Q8-R were used as primers to verify the loss of the ampicillin resistance gene on the genome by PCR, and the strain not induced by IPTG (2533 bp) was used as the control, and the correct transformant had a band at 1326 bp; 50 μL of bacterial solution was applied to a HS solid plate containing 340 μg / mL chloramphenicol resistance and cultured at 30°C for 2 days, which was the second recombinant mutant containing the induced plasmid.

[0066] 5) Loss of inducing plasmid in subculture: The second recombinant mutant containing the inducing plasmid was inoculated into 30 mL HS liquid medium containing 5 U / L cellulase without resistance, and cultured at 30°C and 180 rpm. 600 At about 0.5, 40 μL of bacterial solution was streaked on a non-resistant HS plate and cultured at 30°C for 3 days; single colonies were spotted on HS plates containing 340 μg / mL chloramphenicol resistance and non-resistant, respectively, and cultured at 30°C for 2 days; colonies that grew on non-resistant HS plates but did not grow on chloramphenicol-resistant HS plates were selected, and Q4-F and Q4-R were used as primers to verify the loss of the induced plasmid by PCR, and the second recombinant mutant strain (3775bp) containing the induced plasmid was used as a control, and the correct transformant had no bands; 50 μL of bacterial solution was applied to a HS solid plate and cultured at 30°C for 2 days, namely, the bcsD gene seamless replacement mutant strain.

[0067] 6) Verification and fermentation of bcsD gene seamless replacement mutants: Using Q8-F and Q8-R as primers, PCR was used to verify the gene replacement, and K. xylinus ATCC 53524 (3049 bp) was used as a control. The correct transformant had a band at 3043 bp; using Q8-F, Q8-R, Q9-F and Q9-R as primers, the DNA was sent to Qingke Biotechnology Co., Ltd. for sequencing. The DNA sequencing results are as follows: Figure 8 As shown in A, the acsD gene was successfully replaced with the bcsD gene. K. xylinus ATCC 53524 strain and the bcsD gene seamless replacement mutant were selected, and fermentation and post-treatment were performed according to step 7) in Example 1. The BC yield was measured as shown in Figure 8 As shown in B, compared with K. xylinus ATCC53524, the BC yield of the bcsD gene seamless substitution mutant was significantly reduced (reduced by 57.0%), but the BC morphology after fermentation treatment ( Figure 8B) It can be seen that there are differences in the density and porosity of BC; the sequencing results of the strains and the BC fermentation yield both show Figure 3 The K. xylinus genome scarless replacement method shown was successfully developed, which can be used to study the functions of homologous genes in orthologous, paralogous or heterologous lines, and at the same time, BCs with different structures and properties (such as stretching lightness, crystallinity, molecular weight) can be obtained, thereby being applied to different scenarios and fields.

[0068] The required primers are shown in the following table: Example 4

[0069] This embodiment relates to a P J23104 + Construction and fermentation of RBS scarless insertion mutants, specifically including:

[0070] 1) Construction of p331-bcsA_2 transition plasmid: Using p331-Spc plasmid (Seq ID No.47) as template and W16F and W16R as primers, PCR amplification obtained a plasmid vector fragment with a size of 2906 bp; using K.xylinus ATCC 53524 genome as template and H14-F and H14-R as primers, PCR amplification obtained a bcsA_2 gene fragment with a size of 2305 bp; The PCR one-step directional cloning kit was used to connect the two fragments. Q4-F and S9-R were used as primers, and PCR was used to verify the plasmid construction. The size of the correctly connected plasmid was 4584bp. Q10-F, Q10-R, Q11-F and Q11-R were used as primers and sent to Qingke Biotechnology Co., Ltd. for sequencing, and the p331-bcsA_2 transition plasmid was successfully obtained.

[0071] 2) Construction of suicide plasmid: Using K. xylinus ATCC 53524 genome as template and H15-F and H15-R as primers, PCR amplification was performed to obtain the upstream homology arm fragment of bcsA_2 gene with a size of 1175 bp; using p331-bcsA_2 transition plasmid as template and H16-F and H16-R and H17-F and H17-R as primers, PCR amplification was performed to obtain the upstream homology arm fragment of bcsA_2 gene with a size of 1175 bp. J23104 +RBS and part of the downstream homology arm fragment of bcsA_2 gene and spectinomycin resistance gene fragment, the size of which were 1342bp and 1098bp respectively; using pUC19 plasmid as template and H3-F and H3-R as primers, PCR amplification obtained the replicon fragment, the size of which was 827bp; The PCR one-step directional cloning kit was used to connect the four fragments. Q1-F and Q1-R were used as primers for PCR amplification. The plasmid construction was verified by PCR. The size of the correctly connected plasmid was 3872 bp. Q1-F, Q1-R, Q2-F, Q2-R, Q12-F and Q12-R were used as primers and sent to Qingke Biotechnology Co., Ltd. for sequencing. The Ori replicon and Donor fragment (the upstream homologous arm of the bcsA_2 gene, the I-SceI restriction site, the spectinomycin resistance gene, the I-SceI restriction site, the homologous fragment consistent with the 35 bp sequence of the bcsA_2 gene, the P J23104 +RBS and the downstream homology arm fragment of the bcsA_2 gene) is a suicide plasmid.

[0072] 3) Electroporation and verification of suicide plasmid: The suicide plasmid was electroporated into K.xylinusATCC 53524 competent cells, and after recovery, it was spread on a HS solid plate containing 100 μg / mL spectinomycin resistance and cultured at 30°C for 3 days; multiple transformants were randomly selected and placed in 50 μL HS medium containing 100 μg / mL spectinomycin resistance and 5U / L cellulase, and cultured at 30°C for 2 days; Q13-F and Q13-R were used as primers, and PCR was used to verify the recombination of the Donor fragment, and the K.xylinus ATCC53524 strain (2428bp) was used as a control. The correct transformant had a band at 3591bp; 50 μL of bacterial solution was spread on a HS solid plate containing 100 μg / mL spectinomycin resistance and cultured at 30°C for 2 days, which was the first recombinant mutant strain.

[0073] 4) Electroporation and verification of the inducing plasmid: The inducing plasmid obtained in Example 1 was electroporated into the competent cells of the first recombinant mutant strain, and after recovery, it was applied to a HS plate containing 100 μg / mL of spectinomycin resistance and 340 μg / mL of chloramphenicol resistance, and cultured at 30°C for 3 days; a plurality of transformants were randomly selected to 50 μL HS medium containing 100 μg / mL of spectinomycin resistance, 340 μg / mL of chloramphenicol resistance and 5U / L cellulase, and cultured at 30°C for 2 days; Q4-F and Q4-R were used as primers, and PCR was used to verify the electroporation of the inducing plasmid, and the first recombinant mutant strain (0 bp) was used as a control, and the transformant had a band at 3775 bp; 50 μL of bacterial solution was applied to a HS solid plate containing 100 μg / mL spectinomycin resistance and 340 μg / mL of chloramphenicol resistance, and cultured at 30°C for 2 days, i.e., the first recombinant mutant strain containing the inducing plasmid was obtained.

[0074] 5) IPTG-induced loss of resistance gene: The first recombinant mutant containing the inducible plasmid was inoculated into 4 mL HS liquid medium containing 340 μg / mL chloramphenicol resistance and 5 U / L cellulase and 0.7 mM IPTG, and cultured overnight at 30°C and 180 rpm. 600 When the p value was about 0.4, 70 μL of bacterial solution was streaked on a HS plate containing 340 μg / mL chloramphenicol resistance and 0.7 mM IPTG, and cultured at 30°C for 2 days; single colonies were spotted on HS plates containing 100 μg / mL spectinomycin resistance and no resistance, respectively, and cultured at 30°C for 2 days; colonies that grew on HS plates without resistance and did not grow on HS plates with spectinomycin resistance were selected, and Q13-F and Q13-R were used as primers to verify the loss of spectinomycin resistance genes on the genome by PCR, and the strain not induced by IPTG (3591 bp) was used as a control. The correct transformant had a band at 2475 bp; 50 μL of bacterial solution was applied to a HS solid plate containing 340 μg / mL chloramphenicol resistance and cultured at 30°C for 2 days, which was the second recombinant mutant containing the induced plasmid.

[0075] 6) Loss of inducing plasmid in subculture: The second recombinant mutant containing the inducing plasmid was inoculated into 30 mL HS liquid medium without resistance containing 5 U / L cellulase, and cultured at 30°C and 180 rpm. 600 When the p value was about 0.4, 100 μL of bacterial solution was streaked on a non-resistant HS plate and cultured at 30°C for 2 days; single colonies were spotted on HS plates containing 340 μg / mL chloramphenicol resistance and non-resistant, respectively, and cultured at 30°C for 2 days; colonies that grew on non-resistant HS plates but did not grow on chloramphenicol resistance HS plates were selected, and Q4-F and Q4-R were used as primers to verify the loss of the induced plasmid by PCR, and the second recombinant mutant strain (3775 bp) containing the induced plasmid was used as a control, and the correct transformant had no band; 50 μL of bacterial solution was applied to a HS solid plate and cultured at 30°C for 2 days to obtain P J23104 +RBS scarless insertion mutant.

[0076] 7)P J23104 + RBS scarless insertion mutant verification and fermentation: Q13-F and Q13-R were used as primers to verify the insertion of the gene element by PCR, and K. xylinus ATCC 53524 (2428 bp) was used as a control. The correct transformant had a band at 2475 bp; Q13-F, Q13-R and Q14-F were used as primers and sent to Qingke Biotechnology Co., Ltd. for sequencing. The DNA sequencing results were as follows Fig. 9 As shown in A, P was successfully inserted before the bcsA_2 gene. J23104 +RBS gene element. Select K. xylinus ATCC 53524 strain and PJ23104 +RBS scarless insertion mutant, fermented and post-treated according to step 7) in Example 1, the BC yield measured was as follows Fig. 9 As shown in B, compared with K. xylinus ATCC 53524 strain, P J23104 The BC yield of the +RBS scarless insertion mutant was significantly increased (increased by 14.4%), indicating that the insertion of the promoter and RBS may have overexpressed BC synthesis genes such as bcsA_2, bcsB, acsC_3 and acsD, thereby increasing BC production; the sequencing results of the strain and the BC fermentation yield both showed that Figure 4 The scarless insertion method of K. xylinus genome shown in the figure was successfully developed. This method can insert gene elements such as promoter and RBS before the target gene, and can also insert BC synthesis-related genes at safe sites in the genome, thereby constructing BC stable and high-yield or excellent performance strains.

[0077] The required primers are shown in the following table:

[0078] Compared with the existing technology, this method realizes the scarless knockout, complementation, replacement and insertion operations of the genome of Glucose Acetobacter xylinum by constructing suicide plasmids and inducing plasmids, solves the problem of leaving "scars" on the genome, and can be used for the construction of BC stable and high-yield or excellent performance strains.

[0079] The above-mentioned specific implementation can be partially adjusted in different ways by those skilled in the art without departing from the principle and purpose of the present invention. The protection scope of the present invention shall be based on the claims and shall not be limited by the above-mentioned specific implementation. Each implementation scheme within its scope shall be subject to the constraints of the present invention.

Claims

1. A method for scarless editing of the genome of Gluconacetobacter xylinum, characterized in that: include: 1) Construct a suicide plasmid containing the Donor fragment and an inducible plasmid containing a homing endonuclease (I-SceI); 2) The suicide plasmid is electroporated into competent cells of Gluconacetobacter xylinum, and the Donor fragment is integrated into the genome using the cell's own homologous recombination system to obtain the first recombinant mutant strain; 3) The inducing plasmid is electroporated into the competent cells of the first recombinant mutant strain, and IPTG induces the expression of I-SceI, so that it acts on the I-SceI restriction site integrated in the genome, loses the resistance gene, and obtains the second recombinant mutant strain; 4) The second recombinant mutant was subcultured in a non-resistant HS medium to lose the inducing plasmid, thereby obtaining a mutant strain with no scar editing of the genome of Glucose Acetobacter xylinum.

2. The method for scarless editing of the Gluconacetobacter xylinum genome according to claim 1, characterized in that: The scarless editing includes scarless knockout, scarless backfilling, scarless replacement and scarless insertion, wherein: The traceless knockout means that in step 1), the Donor fragment is a fragment consisting of the Ori replicon, the upstream homologous arm of the knockout gene, the homologous fragment consistent with the downstream 35bp sequence of the knockout gene, the I-SceI restriction site, the resistance gene, the I-SceI restriction site and the downstream homologous arm of the knockout gene; The seamless complementation means that in step 1), the Donor fragment is a fragment consisting of the Ori replicon, the upstream homologous arm of the complementing gene, the complementing gene, the homologous fragment consistent with the downstream 35bp sequence of the complementing gene, the I-SceI restriction site, the resistance gene, the I-SceI restriction site and the downstream homologous arm of the complementing gene; The traceless replacement means that in step 1), the Donor fragment is a fragment consisting of the Ori replicon, the upstream homologous arm of the replacement gene, the gene to be replaced, the homologous fragment consistent with the downstream 35bp sequence of the replacement gene, the I-SceI restriction site, the resistance gene, the I-SceI restriction site and the downstream homologous arm of the replacement gene; The scarless insertion means that in step 1), the Donor fragment is a fragment consisting of the Ori replicon, the homologous arm upstream of the insertion site, the I-SceI restriction site, the resistance gene, the I-SceI restriction site, the homologous fragment consistent with the 35bp sequence upstream of the insertion site, the gene or element and the homologous arm downstream of the insertion site; The I-SceI enzyme is expressed by inducing IPTG, and the concentration of IPTG used is 0.1-1mM; The sequence of the I-SceI restriction site is shown in Seq ID No.1; The resistance gene is an ampicillin resistance gene or a spectinomycin resistance gene.

3. The method for seamlessly editing the genome of Gluconacetobacter xylinum according to claim 1, characterized in that: The inducible plasmid is inserted into the pSEVA331Bb plasmid by inserting the P in the pTKRed plasmid and the pCas9 plasmid. trc -lacI q The inducible plasmid includes pBBR1 Rep protein, OriV replicon, P trc -lacI q Inducible promoter, I-SceI gene, lambdat0 terminator and chloramphenicol resistance gene.

4. The method for scarless editing of the Gluconacetobacter xylinum genome according to claim 1, characterized in that: The subculture refers to: culturing the second recombinant mutant containing the induced plasmid in a non-resistant HS medium, taking single colonies and spotting them on HS plates containing chloramphenicol resistance and non-resistance respectively; selecting colonies that grow on non-resistance HS plates and do not grow on chloramphenicol resistance HS plates, and verifying the loss of the induced plasmid by PCR; if there is no band in the PCR identification gel image, the loss is successful, otherwise the bacterial solution is subcultured until the genome-scarless editing mutant of Glucose Acetobacter xylinum is obtained.

5. The method for scarless editing of the Gluconacetobacter xylinum genome according to claim 1 or 4, characterized in that: The subculture specifically comprises: 1) inoculating the second recombinant mutant containing the inducing plasmid into 30 mL HS liquid medium containing 5 U / L cellulase without resistance, and culturing at 30° C. and 180 rpm; 2) Wait for the bacterial solution OD 600 At 0.4-0.8, take 20-100 μL of bacterial solution and streak it on a non-resistant HS plate and culture it at 30℃ for 1-3 days; 3) Spot single colonies onto HS plates containing 340 μg / mL chloramphenicol-resistant and non-resistant bacteria, and culture at 30°C for 1-2 days; 4) Select the colonies that grow on the non-resistant HS plate but not on the chloramphenicol-resistant HS plate, and verify the loss of the induced plasmid by PCR. If there is no band in the PCR identification gel image, the loss is successful; 5) If the loss fails, take 1 mL of the bacterial solution in step 1) for subculture and spot it on HS plates with different resistances, and repeat the above steps until a strain that successfully loses the induced plasmid is obtained, that is, a mutant strain of the genome of Glucose Acetobacter xylinum with no scar editing.

6. An application of a K. xylinus genome scarless editing mutant obtained by the method according to any one of claims 1 to 5, characterized in that: The K. xylinus genome scarless editing mutant strain was cultured on a plate, and then the BC film was obtained through primary seed culture, secondary seed culture and tertiary fermentation culture. The BC yield was determined after post-fermentation treatment.

7. The use according to claim 6, characterized in that include: 1) Plate culture: The mutant strain of Glucose Acetobacter xylinum that has successfully achieved seamless genome editing is streaked on a non-resistant HS plate and cultured at 30°C for 1-3 days; 2) Primary seed culture: scrape a ring of colonies from the plate, dilute with 1 mL of sterile water, and calculate the initial OD 600 Inoculate 0.02-0.05 of the inoculum into a 250 mL first-level seed bottle containing 30 mL of HS liquid medium and culture at 30°C for 24 h-26 h; 3) Secondary seed culture: Take 2.4 mL of the primary seed solution and transfer it to a 250 mL secondary seed bottle containing 30 mL of HS liquid medium at an inoculum volume of 8%, and culture at 30°C for 24-26 hours; 4) Tertiary fermentation culture: Take 3 mL of the secondary seed solution and transfer it to a 250 mL tertiary fermentation bottle containing 50 mL of fermentation medium at a 6% inoculum amount, and culture it at 30°C for 7-8 days; 5) Post-fermentation treatment: remove the BC membrane and rinse off the culture medium and other impurities with tap water; Add 0.1 mol / L NaOH solution and boil at 80℃ for 0.5-1h to remove the bacteria; soak in tap water for several times until the BC is milky white and the pH is 7.0; place in a constant temperature drying oven at 80℃ to dry, weigh after constant weight, and calculate the BC yield.